MedTrace Logo

Influenza Vaccine Effectiveness of a Quadrivalent Vaccine in Pregnant Women and Young Infants, 2019-2020

NCT04723771 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 949

Last updated 2021-05-11

No results posted yet for this study

Summary

Influenza is associated with an increased risk for serious illness, hospitalization and death in pregnant women and young infants. The investigators estimated the effectiveness of a quadrivalent inactivated influenza vaccine (QIV) in pregnant women and their infants in 2019-2020 influenza season. Women were activelly followed during the influenza season on a weekly basis through telephone call in order to collect data about the onset of fever and/or respiratory symptoms by them or their young infants. Polymerase chain reaction testing in pharyngeal samples was offered to pregnant women and infants with influenza-like illness (ILI). A total of 636 pregnant women and 474 infants were studied. A Bayesian beta-binomial model was used.

Conditions

  • Influenza in Human

Sponsors & Collaborators

  • Hellenic Pasteur Institute

    collaborator UNKNOWN

  • University of Athens

    lead OTHER

Principal Investigators

  • Dimitrios Loutradis, Professor · First Department of Obstetrics and Gynecology, University of Athens

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2020-04-30
Completion
2020-08-31

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04723771 on ClinicalTrials.gov